Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate

Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular cancer research 2019-02, Vol.17 (2), p.446-456
Hauptverfasser: Elfandy, Habiba, Armenia, Joshua, Pederzoli, Filippo, Pullman, Eli, Pertega-Gomes, Nelma, Schultz, Nikolaus, Viswanathan, Kartik, Vosoughi, Aram, Blattner, Mirjam, Stopsack, Konrad H, Zadra, Giorgia, Penney, Kathryn L, Mosquera, Juan Miguel, Tyekucheva, Svitlana, Mucci, Lorelei A, Barbieri, Christopher, Loda, Massimo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Among prostate cancers containing Gleason pattern 4, cribriform morphology is associated with unfavorable clinicopathologic factors, but its genetic features and association with long-term outcomes are incompletely understood. In this study, genetic, transcriptional, and epigenetic features of invasive cribriform carcinoma (ICC) tumors were compared with non-cribriform Gleason 4 (NC4) in The Cancer Genome Atlas (TCGA) cohort. ICC ( = 164) had distinctive molecular features when compared with NC4 ( = 102). These include: (i) increased somatic copy number variations (SCNV), specifically deletions at 6q, 8p and 10q, which encompassed and losses and gains at 3q; (ii) increased and ; (iii) enrichment for and pathways by gene expression; and (iv) increased methylation of selected genes. In addition, when compared with the metastatic prostate cancer, ICC clustered more closely to metastatic prostate cancer than NC4. Validation in clinical cohorts and genomically annotated murine models confirmed the association with ( = 38) and ( = 818). The association of ICC with lethal disease was evaluated in the Health Professionals Follow-up Study (HPFS) and Physicians' Health Study (PHS) prospective prostate cancer cohorts (median follow-up, 13.4 years; = 818). Patients with ICC were more likely to develop lethal cancer [HR, 1.62; 95% confidence interval (CI), 1.05-2.49], independent from Gleason score (GS). IMPLICATIONS: ICC has a distinct molecular phenotype that resembles metastatic prostate cancer and is associated with progression to lethal disease.
ISSN:1541-7786
1557-3125
1557-3125
DOI:10.1158/1541-7786.mcr-18-0440